Is there any difference in insulin resistance status between cases of benign and malignant ovarian neoplasms? A study on surrogate markers of insulin resistance in Indonesian non-diabetic women

HARIYONO WINARTO[1], MUHAMMAD HABIBURRAHMAN[2], IRENE SHINTA FEBRIANA[2], FITRIYADI KUSUMA[1], KARTIWA HADI NURYANTO[1], TRICIA DEWI ANGGRAENI[2], TOFAN WIDYA UTAMI[1] and ANDI DARMA PUTRA[1]

[1]Division of Gynecologic Oncology, [2]Department of Obstetrics and Gynecology, Faculty of Medicine Universitas Indonesia, Dr Cipto Mangunkusumo Hospital, Central Jakarta, DKI Jakarta 10430, Indonesia

Abstract. The association between insulin resistance (IR) and ovarian neoplasm is little known. The present study attempted to investigate the difference in clinicopathological characteristics, metabolic parameters, and IR prevalence between benign and malignant ovarian neoplasms. The cross-sectional study involved 52 non-diabetic women with benign (n=27) and malignant (n=25) diagnoses in a tertiary hospital in Indonesia. Fasting insulin level (FIL), homeostatic model assessment of IR and β-cell dysfunction (HOMA-IR and HOMA-β), fasting IR index (FIRI), and quantitative insulin sensitivity check index (QUICKI) were used as surrogate markers to evaluate IR. Parametric and nonparametric statistical tests were employed to analyze the different parameters between the two groups. Pearson or Spearman's rank test assessed the correlation between markers and clinical variables. Results revealed that patients with benign neoplasms were younger than those with malignant neoplasms (38.63 vs. 47.40 years; P=0.003) and had a higher median body mass index (BMI) than their counterparts (22.98 vs. 18.61 kg/m²; P=0.014). Different characteristics between benign and malignant neoplasm cases were found in menopausal status, ovary side affected, systolic blood pressure, and BMI classes. Endometrial cysts and mucinous carcinoma were the most often diagnosed benign and malignant neoplasms. Malignant neoplasms had a lower median HOMA-β score than benign neoplasms (49.33 vs. 75.79; P=0.011), indicating more severe β-cell dysfunction. No significant difference was observed in the prevalence of IR between benign and malignant ovarian neoplasms for the following values of each marker: FIL (25.9% vs. 12.0%), HOMA-IR (37.0% vs. 28.0%), FIRI (51.9% vs. 48.0%) and QUICKI (81.5% vs. 92.0%). The indicators of FIL, HOMA-IR, HOMA-β, FIRI, and QUICKI correlated with each other and confirmed the reliability of these surrogate markers for measuring IR status in ovarian neoplasms. In brief, benign ovarian neoplasms tended to have more IR when compared with malignant ovarian neoplasms. However, this difference was not statistically significant.

Correspondence to: Dr Hariyono Winarto, Division of Gynecologic Oncology, Faculty of Medicine Universitas Indonesia, Dr Cipto Mangunkusumo Hospital, 6 Salemba Raya Street, Senen, Central Jakarta, DKI Jakarta 10430, Indonesia
E-mail: hariyono.winarto@ui.ac.id

Introduction

Ovarian neoplasm accounts for 6.6% of all female neoplasms (1) and has emerged as one of the most prevalent types of gynecological cancer in Western nations and is also an emerging type of cancer in Asia (2). Ovarian neoplasm survival in Indonesians is poor (3), with its mortality rate surpassing that of cervical and endometrial cancer (4). Ovarian neoplasm is the third most common cancer in women in Indonesia, with incidence rates of 10 per 100,000 individuals, 14,896 new cases in 2020, and a mortality rate of 4.1% (5). According to a recent study, 80% of all ovarian neoplasms are benign (6). Others are malignant, with epithelial ovarian carcinoma (EOC) accounting for 90% of ovarian cancers (7).

The effects of the Western lifestyle have been linked to chronic high blood glucose, obesity, and insulin resistance (IR), all of which are included in metabolic syndrome (MetS) (8). Through insulin-like growth factor (IGF) signaling, IR induces hyperinsulinemia and has a mitogenic and anti-apoptotic effect (9,10). These contribute to the development of multisite cancer (11), especially in individuals who consume more food with a higher glycemic index (12). Hyperinsulinemia has been linked to an increased risk of ovarian cancer in women after menopause (13), and thus it would be another obstacle that would significantly influence cancer outcomes. Several investigations have studied the link between IR and cancer in general (14) and cancer in women, namely cancer of the breast (15-21), endometrium (16,22) and cervix (16). However, despite obesity being a well-known risk factor for ovarian cancer (23), limited evidence supports the role of IR in ovarian neoplasm (16,24,25), and controversies arise regarding whether IR prevalence is different between benign and malignant neoplasms (24-26).

In a previous study of non-diabetic post-menopausal Chinese women with ovarian neoplasms, researchers discovered that the prevalence of ovarian neoplasms was twice as high in the insulin-resistant group as it was in the insulin-sensitive group (16). However, no prior research in Indonesia has studied the difference in IR prevalence between benign and malignant ovarian neoplasms, and no current research has studied surrogate indicators of IR in these two types of ovarian neoplasms. The present study aimed to examine the clinicopathological characteristics, metabolic indicators, and prevalence of benign and malignant ovarian neoplasms in Indonesian women. Fasting insulin level (FIL), homeostatic model assessment of IR (HOMA-IR), homeostasis model assessment of β-cell dysfunction (HOMA-β), fasting IR index (FIRI), and quantitative insulin sensitivity check index (QUICKI) were some of the novels, robust surrogate markers the present study attempted to evaluate in correlation with IR status. The present study also intended to investigate the correlations between the markers and the relationships between the markers and clinical characteristics. Based on IR status and body mass index, it sought to establish a connection between clinicopathological and metabolic variables and ovarian neoplasm grouping by IR status and body mass index (BMI).

Materials and methods

Research design, study population, and inclusion and exclusion criteria. The present study was an analytical cross-sectional study investigating surrogate markers of IR in benign and malignant ovarian neoplasms patients in Dr. Cipto Mangunkusumo Hospital, a referral hospital for cancer in Indonesia, between October 2019 and 2020. The minimum required sample was calculated using a statistical formula for a comparative test of numerical data of two unpaired groups that were carried out in one measurement (27,28) as stated below:

$$n_1 = n_2 = 2\left(\frac{[z_\alpha + z_\beta]^2 \pi}{X_1 - X_2}\right)^2$$

In this formula, 'n_1 and n_2' denoted the number of subjects in each group (benign and malignant). 'Z_α' was the standard value of α obtained from the z-curve, with a value of 1.96, and 'Z_β' is the standard value of type two error (β=0.8), with a value of 0.84. The notation of 'π' is the sum of two standard deviations (SDs) of HOMA-IR, as a common marker of IR, in the malignant group (SD=0.5) and benign group (SD=0.6) of ovarian neoplasm and thus π value was 1.1 (24). The mean score difference of the HOMA-IR deemed significant between the two groups was indicated by 'X_1-X_2', with 2.8 being the value judged by the researchers to be significantly different (a prior study determined it as 0.5, but the result was not statistically significant) (24).

Following calculation, the present study obtained a minimum number of subjects per group of 18.97 (~19). However, it adopted a consecutive nonrandom sampling method and enlisted 80 subjects with ovarian cysts suspected as neoplasms who were admitted to inpatient or outpatient services in the ward. Fig. 1 describes the selection of subjects based on inclusion and exclusion criteria. After all eligible patients had given informed consent, transvaginal, transabdominal, or transrectal ultrasound (US) was performed by an experienced examiner to initially classify the neoplasms as benign or malignant while waiting for histopathological confirmation. The initial grouping followed the assessment of different neoplasias in the adnexa risk model developed by the International Ovarian Tumor Analysis (IOTA) (29,30). Clinical characteristics and blood sampling were obtained preoperatively, and histopathological examination results confirmed the final grouping after the surgical procedure (resection or biopsy).

Data extraction, measurement of parameters, and definition of variables. Data were extracted from the identity cards of patients, history, and medical records. Sociodemographic variables included the hometown, age, education, and occupation of patients. The province where the patient resided within the last year was recorded based on the identity card and domicile letter (31). The rurality variable was created by categorizing the patients' domicile into rural, suburban, and urban areas based on the Indonesian Statistics Agency data (32-34). The age was classified into ranges per decade and categorized into young (≤40 years) and old age (>40 years) based on productivity and reproductive age (35,36) and relevant studies (37,38). Formal education was categorized based on their level of educational status to be low level [primary and junior high school (JHS)] or high-level education [senior high school (SHS) and bachelor's degree] (39). Employment status was categorized as employed or unemployed (39).

The present study analyzed parity status, contraception use, menopausal status and age, specimen type, affected ovarium site (left/right), cancer stage, and histopathological examination results through medical records, surgical reports, and pathological reports. A prior study classified parity status into nulliparous, primiparous, and multiparous (3). Contraception status was classified by different methods of contraception that the subjects had ever used, such as hormonal or non-hormonal contraception, pill or non-pill, and injection or non-injection (3). Menopausal status was defined as a cessation of the menstrual cycle for 12 months and was classified based on a prior study (3). Specimen types were divided into biopsy or resection specimens. The history of cancer pointed to the presence of any malignancies in the close/nuclear family. The affected side of the ovary included the left, right,

Figure 1. Flow diagram of subjects designated in the research analysis. Participants were selected following inclusion and exclusion criteria before inputting medical record data and ultrasound assessment. Some patients were excluded from the cohort after blood sampling and histopathological confirmation. Changes in the diagnosis from benign to malignant neoplasms and vice versa adjusted the number of cases in these two groups of ovarian neoplasm for the final analysis. ALT, alanine transaminase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, γ-glutamyl transferase; and BMI, body mass index.

or bilateral ovary depending on the location of the neoplasm found at diagnosis. The cancer stage was grouped as early (I-II) and advanced stage (III-IV) cancer, as classified by The International Federation of Gynecology and Obstetrics (40). Experienced gynecological-oncologist consultants performed the determination of the cancer stage. Histopathological examination results were obtained from post-surgical samples and confirmed benign or malignant pathological diagnoses and other concurrent pathological findings based on World Health Organization (WHO) criteria (41). The malignant neoplasms can histologically be classified as an epithelial, germ cell, sex cord-stromal, other specific non-epithelial, and non-specific histological types (42).

The present study measured blood pressure (BP) and documented prior hypertension history, BMI, fasting plasma

glucose (FPG), and FIL in metabolic parameters. The systolic and diastolic blood pressure (SBP and DBP) were doubly measured using a clinically validated digital sphygmomanometer (Omron HEM-7120; OMRON Healthcare Asia) with a standard protocol of measurement of BP (43). The results of SBP and DBP were classified based on the 2020 Global Hypertension Practice Guidelines (43). BMI was computed using height and weight data from calibrated hospital scales following adult anthropometrics standard procedures (44). The Asia Pacific standard's specific threshold was applied to classify BMI (45), which was then divided into two groups (normal + underweight and overweight + obese).

All blood sampling and recording of clinical data were performed before surgery. A venous blood sample was taken to measure FPG and FIL in the morning after overnight fasting.

Following universal standard precautions, 6 ml of peripheral venous blood was collected from the antecubital vein by venipuncture into red and grey sterile Vacutainer tubes from participants who had fasted overnight (8-12 h) (46). Blood in the grey tube was used for FPG analysis using a hexokinase enzymatic reference method (47). Meanwhile, blood in the red tube was chilled immediately and allowed to clot within 30-45 min. Then, the clotted blood was centrifuged at 1,300-2,000 x g for 15 min at 4˚C. After obtaining the serum (supernatant), it and the aliquot were put into two sample cups, each with a volume of 0.5 ml. The remaining aliquots were stored at -80˚C until assayed. The procedures used in this investigation were based on a previous study (48).

Insulin was quantified using the chemiluminescence technique with a standardized ADVIA Centaur ReadyPack assay (Bayer AG). The ADVIA insulin examination is a two-site sandwich immunoassay using direct chemiluminescence technology, employing two antibody types. The first antibody, in Lite Reagent, is a labeled mouse insulin monoclonal antibody conjugated to acridinium ester. The second antibody, a solid-phase mouse insulin monoclonal antibody, was attached to a paramagnetic particle. These two antibodies react with the insulin in the sample and produce a luminescent emission captured by the photomultiplier and translated into a Relative Light Unit (RLU). This RLU value is proportional to the insulin concentration in the sample. This process was referred to in a study by Gupta *et al* (49).

The present study employed three FPG criteria as given in the guidelines by the American Diabetes Association in 2022 (50). Criteria for high FIL were defined from receiver operating characteristic (ROC) curve analyses in a previous study with a cut-off of <7 μIU/ml to exclude IR (51). The present study employed several surrogate markers [i.e., HOMA-IR (52,53), HOMA-β (52-55), FIRI (56-58), and QUICKI (59-62)] with the following equations to quantify IR prevalence:

$$HOMA - IR = \text{fasting insulin level} \left(\frac{\mu IU}{ml} \right) \times \frac{\text{fasting plasma glucose} \left(\frac{mg}{dL} \right)}{405}$$

$$HOMA - \beta = 360 \times \frac{\text{fasting insulin level} \left(\frac{\mu IU}{ml} \right)}{\text{fasting plasma glucose} \left(\frac{mg}{dL} \right) - 63} \%$$

$$FIRI = \frac{\text{fasting insulin level} \left(\frac{mg}{dL} \right)}{18} \times \frac{\text{fasting insulin level} \left(\frac{\mu IU}{ml} \right)}{25}$$

$$QUICKI = \frac{1}{[\log \text{fasting insulin level} (\mu IU/ml)] + [\log \text{fasting plasma glucose} (mg/dL)]}$$

HOMA-IR was used to evaluate IR and calculated with a HOMA calculator released in MDCalc (mdcalc.com/homa-ir-homeostatic-model-assessment-insulin-resistance). The present study used a cut-off of HOMA-IR specific for Indonesian women with IR and MetS with a value of ≥1.208 noted as IR and 'normal' if the result is <1.208 (63).

HOMA-β classification depicts the function of the pancreatic β-cells (64). The classification used for the HOMA-β tests was determined by an Asian study from Japan using a cut-off point by tertile: ≤76.25 (low value; suggesting β-cell dysfunction); 76.25-122.13 (medium value; indicating normal β-cell function); and ≥122.13 (high; suggesting the excessive function of insulin secretion in β-cells, commonly found in central obesity) (53).

Duncan *et al* (57) formulated FIRI derived from FIL and FPG, which has been validated as an empirical IR index against the hyperinsulinaemic-euglycaemic clamp (HEC) (65). The original formula for FIRI in a previous study used FPG in mmol/l (66), hence the present study modified it to be adjusted in mg/dl by dividing the FPG by 18 [FPG (mmol/l)=FPG (mg/dl)/18] (67). A lower result of FIRI reflected a normal-level value, and the cut-off >0.77 denoted IR based on the AUC value in a prior study (68).

The QUICKI is the inverse of the HOMA-IR and assesses insulin sensitivity instead of IR (69) and a value <0.339 indicated IR (59-62).

Ethical clearance. An Institutional Ethical Reviewer Board from the Faculty of Medicine Universitas Indonesia authorized this research, with the ethical clearance number KET-1091/UN2.F1/ETIK/PPM.00.02/2019. The eligible subjects gave full written consent to this research regarding the present study's purpose and procedure. This study followed the Strengthening the reporting of observational studies in epidemiology checklist guidelines for cross-sectional studies (70).

Statistical analysis. All collected data were analyzed using the Statistical Package for the Social Sciences software (v24; IBM Corp.) and visualized using Microsoft Excel for Microsoft 365 MSO (v2205; 32-bit edition; Microsoft Corporation). After completing a Levene's test for homogeneity of variances following the normality test using the Kolmogorov-Smirnov or Shapiro-Wilk tests, normally distributed continuous data were expressed as a mean score and standard error or as median score [interquartile ranges (IQR)] if they were skewed in distribution. Employing an independent Student's t-test or its alternate statistical test (the Mann-Whitney U test), numerical data of clinical and metabolic parameters were compared between cases of benign and malignant neoplasms, whereas for categorical data, χ^2 or Fisher exact tests were used.

P<0.05 indicated a statistically significant difference with a 95% confidence interval (CI). Pearson's correlation analysis or Spearman's rank test was used depending on data variance. Their correlation value (r) or rho degree (ρ) was interpreted according to the standard: 0, no correlation; 0.01-0.2, very weak correlation; 0.2-0.4, weak correlation; 0.4-0.6, moderate correlation; 0.6-0.8, strong correlation; 0.8-1, very strong correlation; and 1, monotonic correlation (71).

Results

Sociodemographic, clinicopathological and metabolic profiles. In the present study, 52 subjects were selected, consisting of 27 (51.92%) with benign neoplasm and 25 (48.08%) with malignant neoplasm. The majority of the patients came from urban areas (67.3%), then suburban areas (19.2%), and then rural areas (13.5%). Five different provinces were identified, with residents of Jakarta representing the majority of participants (53.9%), followed by those from West Java (26.9%), Banten (15.4%), Bangka Belitung (1.9%), and Yogyakarta (1.9%). Unemployed subjects made up 61.5% of the population. More than 60% of women had a high level of formal education, including a bachelor's degree (19.2%) and SHS (42.3%). Meanwhile, almost 40% of women possessed a low level of formal education comprised of primary school

Table I. Comparison of patient's sociodemographic and clinical characteristics between the two ovarian neoplasm classifications.

| Characteristics | Ovarian neoplasms | | | | | | P-value |
| | Benign | | Malignant | | Total | | |
	n	%	n	%	n	%	
Age (years)							0.123[a]
11-20	1	3.7	0	0	1	1.9	
21-30	8	29.7	1	4.0	9	17.3	
31-40	7	25.9	6	24.0	13	25.0	
41-50	6	22.2	8	32.0	14	26.9	
51-60	4	14.8	9	36.0	13	25.0	
61-70	1	3.7	1	4.0	2	3.9	
Age category (years)							0.023[a]
Young (≤40)	16	59.3	7	28.0	23	44.2	
Old (>40)	11	40.7	18	72.0	29	55.8	
Marital status							>0.999[b]
Married	23	85.2	22	88.0	45	86.5	
Unmarried	4	14.8	3	12.0	7	13.5	
Parity status							0.449[a]
Nulliparous	9	33.3	8	32.0	17	32.7	
Primiparous	3	11.1	6	24.0	9	17.3	
Multiparous	15	55.6	11	44.0	26	50.0	
Menopausal status							0.026[a]
Yes	6	22.2	13	52.0	19	36.5	
No	21	77.8	12	48.0	33	63.5	
Fertility drug use							>0.999[b]
Yes	1	3.7	1	4.0	2	3.8	
No	26	96.3	24	96.0	50	96.2	
Malignancy history in the family							>0.999[b]
Yes	1	3.7	1	4.0	2	3.8	
No	26	96.3	24	96.0	50	96.2	
Contraception use							0.242[a]
No	21	77.8	16	64.0	37	71.2	
Pill	2	7.4	1	4.0	3	5.8	
DMPA	0	0	4	16.0	4	7.7	
DMPA, pill	3	11.1	1	4.0	4	7.7	
DMPA, IUD	0	0.0	1	4.0	1	1.9	
IUD	1	3.7	1	4.0	2	3.8	
IUD, pill	0	0	1	4.0	1	1.9	
Contraception type							0.262[a]
None + non-hormonal	22	81.5	17	68.0	39	75.0	
Hormonal	5	18.5	8	32.0	13	25.0	
Oral contraception use							0.705[b]
No	22	81.5	22	88.0	44	84.6	
Yes	5	18.5	3	12.0	8	15.4	
Injection contraception use							0.284[b]
No	24	88.9	19	76.0	43	82.7	
Yes	3	11.1	6	24.0	9	17.3	
Specimens from diagnostic procedures							0.002[a]
Biopsy	9	33.3	0	0	9	17.3	
Resection	18	66.7	25	100.0	43	82.7	

Table I. Continued.

Characteristics	Benign		Malignant		Total		P-value
	n	%	n	%	n	%	
Ovarium side affected							0.036[b]
Left	5	18.5	8	32.0	13	25.0	
Right	6	22.2	11	44.0	17	32.7	
Bilateral	16	59.3	6	24.0	22	42.3	
SBP (mmHg)							0.043[a]
Normal (<130)	17	63.0	11	44.0	28	53.8	
High-normal (130-139)	8	29.6	4	16.0	12	23.1	
Grade I (140-159)	2	7.4	8	32.0	10	19.2	
Grade II (≥160)	0	0	2	8.0	2	3.9	
DBP (mmHg)							0.377[a]
Normal (<85)	18	66.7	13	52.0	31	59.6	
High-normal (85-89)	7	25.9	6	24.0	13	25.0	
Grade I (90-99)	2	7.4	5	20.0	7	13.5	
Grade II (≥100)	0	0	1	4.0	1	1.9	
Prior hypertension history							0.053[a]
No	20	74.1	12	48.0	32	61.5	
Yes	7	25.9	13	52.0	20	38.5	
BMI Asia-Pacific classification (kg/m^2)							0.061[a]
Underweight (<18.5)	4	14.9	11	44.0	15	28.9	
Normal (18.5-22.9)	10	37.0	9	36.0	19	36.5	
Overweight (23-24.9)	8	29.6	2	8.0	10	19.2	
Obese (≥25)	5	18.5	3	12.0	8	15.4	
BMI class							0.033[a]
Lower-class BMI (normal + underweight)	14	51.9	20	80.0	34	65.4	
Higher-class BMI (overweight + obese)	13	48.1	5	20.0	18	34.6	

[a]χ^2 test; [b]Fisher exact test. SHS, senior high school; DMPA, depot-medroxyprogesterone acetate; IUD, intrauterine device; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index.

(21.2%) and JHS (17.3%). Subjects had a mean age of 42.9±11.0 (range 17-65 years). As shown in Table I, the proportion between young and old patients was comparable (55.8% vs. 44.2%), corresponding with the significantly different mean score between patients with benign and malignant neoplasms (38.63±11.43 vs. 47.40±8.63, P=0.003) in Table II. The majority of the participants were married, had multiple children, were not menopausal, did not use contraception, had no family history of cancer, had both ovaries affected by tumors, had normal levels of SBP and DBP, did not previously have hypertension, and were within the normal weight range according to BMI.

The differences in sociodemographic and clinical characteristics between benign and malignant ovarian neoplasms cases were found in the variable of age category (P=0.023), menopausal status (P=0.026), specimen taking (P=0.002), affected side of ovary (P=0.036), SBP (P=0.043), and BMI class (P=0.033). Table II shows that the patients with malignant neoplasms had a lower mean score of BMI than those with benign tumors [18.61 (IQR: 17.97-21.32) vs. 22.98 (20.08-24.44),

P=0.014]. It also demonstrates that malignant cases had a lower median HOMA-β score than their counterparts [49.33 (IQR: 28.06-84.44) vs. 75.79 (IQR: 59.29-102.86), P=0.011].

As illustrated in Table III, the most frequent diagnosis in cases of benign neoplasms was an endometrial cyst (59.3%), followed by mucinous cystadenoma (25.9%) and mature teratoma (18.5%). Mucinous carcinoma (40% of all malignant neoplasm cases), clear cell carcinoma (24%), and adenocarcinoma (16%) were the three most prevalent malignant neoplasm types. Among the malignant cases, 5 patients (20%) had stages I-II, and 20 patients (80%) had stages II-IV of the disease.

Prevalence of IR in ovarian neoplasms. The prevalence estimation of IR among Indonesian patients with ovarian neoplasms ranged from 19.2% using FIL to 86.5% using QUICKI, depending on the selected surrogate marker (Table IV). According to these results, β-cell dysfunction affected 61.5% of patients concurrently. For any application of the markers, there was no statistically significant difference

Table II. Differences in mean or median values of clinical characteristics of patients and metabolic parameters between the two ovarian neoplasm classifications.

Variables	Mean ± SD or median (IQR)			P-value[a]
	Benign ovarian neoplasms	Malignant ovarian neoplasms	All cases	
Age (years)	38.63±11.43	47.40±8.63	42.85±11.01	0.003[b]
Menopausal age (years)	48.50±4.37	48.08±4.37	48.21±4.25	0.847[b]
SBP (mmHg)	121.70±13.14	129.40±17.88	125.40±15.92	0.081[b]
DBP (mmHg)	80.00 (78.00-85.00)	84.00 (79.00-89.50)	82.00 (78.00-87.75)	0.078[c]
BMI (kg/m²)	22.98 (20.08-24.44)	18.61 (17.97-21.32)	20.39 (18.36-24.19)	0.014[c]
FPG (mg/dl)	82.00 (79.00-96.00)	94.00 (78.00-100)	84.00 (79.25-96.00)	0.241[c]
FIL (μIU/ml)	3.20 (4.20-7.70)	3.60 (2.75-5.15)	4.00 (2.95-5.87)	0.105[c]
HOMA-IR	0.82 (0.57-1.73)	0.79 (0.54-1.29)	0.82 (0.58-1.50)	0.318[c]
HOMA-β (%)	75.79 (59.29-102.86)	49.33 (28.06-84.44)	65.14 (42.91-99.07)	0.011[c]
FIRI	0.81 (0.54-1.56)	0.74 (0.54-1.16)	0.76 (0.54-1.35)	0.327[c]
QUICKI	0.39 (0.35-0.42)	0.40 (0.37-0.42)	0.39 (0.36-0.42)	0.307[c]

[a]P-value indicated the statistical differences between benign and malignant neoplasms group; [b]Student's t-test, equal variances assumed; [c]Mann-Whitney U test. SD, standard deviation; IQR, interquartile range; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; FIL, fasting insulin level; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell dysfunction; FIRI, fasting insulin resistance index; QUICKI, quantitative insulin sensitivity check index.

in the prevalence of IR and β-cell dysfunction between benign and malignant cases. However, subjects with benign neoplasms tended to have IR more commonly (FIRI, 51.9% vs. 48%; HOMA-IR, 37% vs. 28%; and FIL, 25.9% vs. 12%). On the other hand, malignant neoplasms tended to have more significant β-cell dysfunction according to HOMA-β (72% vs. 51.9%) and more frequent IR according to QUICKI (92% vs. 81.5%). All cases with high FPG ≥126 mg/dl (n=2) also belonged to malignant neoplasms cases.

Correlation between clinical features and surrogate markers. Three different correlation analyses were performed among markers, and between markers and clinical features, done in the overall subject pool, and the benign and malignant ovarian neoplasm groups, respectively. As shown in Fig. 2A, there was a strong positive correlation between FIL and FIRI, HOMA-IR and FIRI, age and menopausal age, and FIL and HOMA-IR among all ovarian neoplasm cases. There was also a strong negative correlation between QUICKI and FIRI, QUICKI and FIL, and QUICKI and HOMA-IR. Fig. 2B shows that among the 'benign group,' there was a strong positive correlation between FIL and FIRI, HOMA-IR and FIRI, and FIL and HOMA-IR. A strong negative correlation was also discovered between QUICKI and FIRI, QUICKI and FIL, and QUICKI and HOMA-IR. Fig. 2C expresses a significant positive correlation among the malignant group between FIRI and FIL and between FIRI and HOMA-IR; meanwhile, a strong negative correlation was identified between QUICKI and FIRI, QUICKI and FIL, and QUICKI and HOMA-IR.

Association between patients' characteristics and ovarian neoplasms according to IR and BMI. Table V shows that the difference between the two groups of IR status (non-IR vs.

IR) was observed among the benign neoplasm group in the median score of FIL (P<0.001) and HOMA-β (P=0.031), as well as in the mean scores of FPG (P=0.004), FIRI (P<0.001), and QUICKI (P<0.001). Meanwhile, among the malignant neoplasms group, the mean score of FPG (P=0.002) and the median score of FIL (P=0.001), FIRI (P<0.001), and QUICKI (P<0.001) were significantly different between the IR and non-IR groups. More detailed analysis in Table SI (in categorical data) revealed that among benign neoplasms cases, parity status (P=0.039), FPG (P=0.041), FIL (P<0.001), FIRI (P<0.001), and QUICKI (P=0.012) differed between the two groups of IR status. Meanwhile, the parameters of FPG (P=0.036), FIL (P=0.015), and FIRI (P=0.002) were shown to differ between the non-IR and IR groups among malignant neoplasm cases.

The difference between 'higher-class' and 'lower-class' BMI status among benign and malignant patients was examined in Table VI. Among patients with benign neoplasms, it was discovered that the median score of FPG (P=0.017) and HOMA-β (P=0.023) was significantly different between the two groups of BMI status (overweight + obese vs. normal + underweight). Meanwhile, among patients with malignant diagnoses, there was no significant variation in mean/median score parameters between the two groups of BMI status. Further categorical data analysis, as the details attached in Table SII, revealed a significant difference in DBP (P=0.009), hypertension status (P=0.039), and HOMA-β (P=0.041) variables between the two BMI statuses within the malignant neoplasms group.

Association between characteristics of patients and histopathological types of ovarian cancer. There was no significant variation in patient characteristics regarding clinical, metabolic,

Table III. Description of histopathological diagnosis in the benign and malignant ovarian neoplasm cases.

	Total	
Histopathological diagnosis	n	%
Primary ovarian neoplasm diagnosis		
Benign pathology	27	51.9
Malignant pathology	25	48.1
Presented benign histopathological diagnosis[a]		
Endometrial cyst	16	59.3
Mucinous cystadenoma	7	25.9
Mature teratoma	5	18.5
Dermoid cyst	3	11.1
Ovarian abscess	3	11.1
Chronic xanthogranuloma oophoritis	2	7.4
Brenner tumor	1	3.7
Seromucinous cystadenoma	1	3.7
Cellular fibroma	1	3.7
Presented malignant histopathological diagnosis		
Mucinous carcinoma	10	40.0
Clear cell carcinoma	6	24.0
Adenocarcinoma	4	16.0
Endometrioid carcinoma	2	8.0
Serous carcinoma	2	8.0
Mixed type (mucinous carcinoma and clear cell carcinoma)	1	4.0

[a]Since some patients may display more than one benign neoplasm diagnosis in the pathological examination; thus, multiple responses were recorded and analyzed.

and IR indicators among histopathological types of malignant ovarian neoplasm, as shown in Table VII and Table SIII. However, patients with serous carcinoma seemed to have the oldest age, the oldest age at which menopause occurs, the greatest BMI score, the highest FIL, the highest HOMA-IR, and the greatest FIRI. Meanwhile, the mixed histopathological type group had the highest SBP, DBP, and FPG levels and the lowest BMI and HOMA-β score. These two subtypes also shared the lowest QUICKI results.

Discussion

Limited evidence is available on the association of IR with ovarian neoplasm (16,24,49), particularly among Southeast Asians. Thus the present study investigated whether there is a difference in IR between benign and malignant ovarian neoplasm since IR plays a vital role in FIL homeostasis related to cancer.

Characteristics of patients with benign and malignant ovarian neoplasms. Not surprisingly, due to the massive urbanization and adoption of a sedentary lifestyle associated with Western society in Indonesia, the patients in the present study predominantly came from urban areas with high education levels. This lifestyle may lead to a rising incidence of obesity-related comorbidities, including ovarian neoplasms, as observed in urban areas of China compared with rural areas (2,72,73).

Nevertheless, living in an urban area with a high education does not guarantee that patients will be diagnosed early since cases in the present study were predominantly in advanced-stage diseases (80%). Indeed, ~75% of cases of ovarian cancer are diagnosed at a late stage due to the non-specific nature of symptoms and the absence of practical screening tests (49).

The present study revealed that most of the patients were old (>40 years), similar to a study conducted in India (49), with young women mostly having benign ovarian neoplasm (Table I). Meanwhile, older women were more commonly involved in malignant cases. Different ages were also found to exhibit different histological subtypes; serous subtypes were more common in older patients and adenocarcinoma in younger patients. Generally, a younger age pattern was found among all histological subtypes compared with a study by Otokozawa *et al* (25). The present study found no significant difference in other clinical risk factors of ovarian cancer, such as menopausal status, parity, and contraceptive use, between malignant and benign neoplasm patients, similar to a prior study in India (49).

There were no differences in the clinicopathological characteristics of patients with ovarian neoplasm according to IR status, BMI status, cancer stage, and histological subtypes among the benign and malignant case groups. However, the present study found a higher proportion of patients with high SBP (grade I and II) in malignant compared with benign neoplasms (40% vs. 7.4%; P<0.05). Hypertension is

Table IV. Comparison of metabolic parameters related to the prevalence of insulin resistance between the two ovarian neoplasm classifications.

| | Ovarian neoplasms | | | | | | |
| | Benign | | Malignant | | Total | | |
Parameters	n=	%	n=	%	n=	%	P-value
FPG (mg/dl)							0.193[a]
Normal (<100)	24	88.9	18	72.0	42	80.8	
Moderate (100-125)	3	11.1	5	20.0	8	15.4	
High (≥126)	0	0	2	8.0	2	3.8	
FIL (μIU/ml)							0.296[b]
Normal (<7)	20	74.1	22	88.0	42	80.8	
IR (≥7)	7	25.9	3	12.0	10	19.2	
HOMA-IR							0.488[a]
Normal (<1.208)	17	63.0	18	72.0	35	67.3	
IR (≥1.208)	10	37.0	7	28.0	17	32.7	
HOMA-β (%)							0.300[a]
Normal β-cell function (76.25-122.13)	8	29.6	5	20.0	13	25.0	
Beta cell dysfunction (≤76.25)	14	51.9	18	72.0	32	61.5	
Beta cell excessive function (≥122.13)	5	18.5	2	8.0	7	13.5	
FIRI							0.781[a]
Normal (≤0.77)	13	48.1	13	52.0	26	50.0	
IR (>0.77)	14	51.9	12	48.0	26	50.0	
QUICKI							0.352[b]
Normal (>0.339)	5	18.5	2	8.0	7	13.5	
IR (≤0.339)	22	81.5	23	92.0	45	86.5	

[a]χ^2 test; [b]Fisher exact test. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; FIL, fasting insulin level; IR, insulin resistance; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell dysfunction; FIRI, fasting insulin resistance index; QUICKI, quantitative insulin sensitivity check index.

an age-related disease, and those with malignant ovarian neoplasm are more commonly elderly. Hypertension may occur in these patients due to psychological states or pain, involving a maladaptive nociceptive system (74). IR, which is associated with activation of the renin-angiotensin-aldosterone system and sympathetic nervous system activities, could also contribute to the patients' high blood pressure in this study (75).

The most intriguing finding of the present study was that those with benign ovarian neoplasms were more likely to be overweight or obese compared with those with malignant neoplasms. In this study, the predominance of patients with a lower BMI status in malignant neoplasms was probably related to protein-energy wasting caused by chronic leptin dysregulation due to persistent systemic inflammation (76). This process leads to reduced appetite and intake, weight loss, malnutrition, and possibly cachexia (77). The results were comparable to a study in South Korea that found that underweight and normal BMI prevalence in advanced-stage ovarian cancer was 44% (vs. 3.3%) and 36% (vs. 45%), respectively (78). Wright et al (79) also confirmed that women having 'normal' BMI categories (35.2%) are more likely to suffer malignant ovarian neoplasm compared with overweight (23.9%) or obese

(25.8%) women. Nevertheless, according to a study in the US, BMI demonstrated a poor positive association with ovarian cancer (OR 1.14, 95% CI: 0.86-1.51) (80).

Measuring IR in benign and malignant ovarian neoplasms. In Indonesia, there is no established investigation on surrogate markers for IR in ovarian neoplasms, and there is no universally accepted definition of IR based on these various markers. The present study enrolled non-diabetic women with benign and malignant neoplasms to measure their IR status using numerous surrogate markers proposed in the literature (56). Accordingly, the prevalence of IR in the Indonesian patients in the present study ranged from 19.2-86.5% in overall cases depending on different markers used, 25.9-81.5% in the benign case group, and 12-92% in the malignant case group, varying based on the diagnostic markers and selected cut-offs used. These numbers were comparable with the prevalence of IR in benign cases (28.7%) and malignant cases of breast neoplasm (64.0%) in Turkey (15), as well as the prevalence of IR in endometrial carcinoma (80%) in China (22). IR prevalence is attributed to different populations, inclusion criteria, markers, and cut-offs to define IR. In the investigation of IR,

A. All neoplasms

	Age	Menopausal age	BMI*	SBP	log_DBP	FPG*	log_FIL	HOMA-IR*	HOMA-β*	log_FIRI	log_QUICKI
Age	1.000	0.892[a]	-0.034	0.193	0.357[b]	0.278[f]	-0.130	-0.016	-0.298	-0.053	0.053
Menopausal age		1.000	0.072	0.171	0.214	0.333	0.089	0.312	0.134	0.103	-0.090
BMI*			1.000	0.000	0.082	-0.191	0.205	0.065	0.417[e]	0.109	-0.100
SBP				1.000	0.561[a]	0.169	0.041	0.145	-0.016	0.097	-0.114
log_DBP					1.000	0.101	0.030	0.011	-0.008	0.083	-0.087
FPG*						1.000	0.367[b]	0.646[d]	-0.416[e]	0.570[d]	-0.578[d]
log_FIL							1.000	0.840[d]	0.571[d]	0.974[a]	-0.962[a]
HOMA-IR*								1.000	0.261	0.921[d]	-0.914[d]
HOMA-β*									1.000	0.385[e]	-0.378[e]
log_FIRI										1.000	-0.996[e]
log_QUICKI											1.000

B. Benign neoplasms

	Age	Menopausal age	BMI	SBP	DBP	FPG*	Log FIL	HOMA-IR*	HOMA-β*	Log FIRI	QUICKI
Age	1.000	0.797	0.109	-0.287	0.371	0.217	-0.069	-0.013	-0.213	0.016	-0.019
Menopausal age		1.000	0.254	0.300	-0.207	0.543	0.382	0.429	0.254	0.432	-0.371
BMI			1.000	-0.049	0.007	-0.501[e]	-0.017	-0.204	0.310	-0.093	0.112
SBP				1.000	0.519[b]	0.080	0.138	0.196	0.085	0.130	-0.121
DBP					1.000	-0.030	0.112	-0.006	0.052	0.106	-0.150
FPG*						1.000	0.271	0.492[e]	-0.428[f]	0.410[f]	-0.415[f]
Log FIL							1.000	0.888[d]	0.720[d]	0.985[a]	-0.973[a]
HOMA-IR*								1.000	0.471[f]	0.926[d]	-0.920[d]
HOMA-β*									1.000	0.585[e]	0.590[e]
Log FIRI										1.000	-0.993[a]
QUICKI											1.000

C. Malignant neoplasms

|	Age	Menopausal age*	BMI*	SBP	DBP	FPG	FIL*	HOMA-IR*	HOMA-β*	Log FIRI	QUICKI*
Age	1.000	0.701	0.069	-0.074	0.160	0.191	0.175	0.093	-0.156	-0.067	-0.191
Menopausal age*		1.000	0.014	0.050	0.266	0.097	0.359	0.142	0.320	0.308	-0.323
BMI*			1.000	0.141	0.330	0.023	0.318	0.187	0.413[f]	0.234	-0.234
SBP				1.000	0.554[b]	0.306	-0.047	0.198	0.059	0.159	-0.110
DBP					1.000	0.356	0.013	0.100	-0.017	0.177	-0.101
FPG						1.000	0.458[f]	0.797[d]	-0.328	0.608[b]	-0.731[d]
FIL*							1.000	0.776[d]	0.448[f]	0.933[d]	-0.929[d]
HOMA-IR*								1.000	0.088	0.919[d]	-0.904[d]
HOMA-β*									1.000	0.224	-0.205
Log FIRI										1.000	-0.996[d]
QUICKI*											1.000

Figure 2. Correlation plot between clinical features and surrogate markers of insulin resistance among the entire, benign, and malignant case groups. (A) Among all ovarian neoplasm cases, the highest positive correlation was revealed between FIL and FIRI (r=0.974), and the strongest negative correlation was found between FIRI and QUICKI (ρ=-0.996). (B) Considering benign cases, FIL possesses the most potent positive correlation with FIRI (r=0.985), and FIRI was most negatively correlated with QUICKI (r=-0.993). (C) In the sub-analysis for malignant cases, FIL and FIRI had the most robust positive correlation (ρ=0.933); meanwhile, FIRI and QUICKI possessed the firmest correlation value with ρ=-0.996. [a]$P<0.001$ from Pearson's correlation test; [b]$P<0.01$ from Pearson's correlation test; [c]$P<0.05$ from Pearson's correlation test; [d]$P<0.001$ from Spearman's rank correlation test; [e]$P<0.01$ from Spearman's rank correlation test; [f]$P<0.05$ from Spearman's rank correlation test. *Skewed data distribution in the normality test using the Kolmogorov-Smirnov test for overall patients and the Shapiro-Wilk test for respectively the benign and malignant case groups, although adjustments for normalization have been made. Thus, the usual correlation test was Spearman's statistical test; other variables without asterisks were tested using the Pearson correlation test. Logarithmic variables resulted from transformed variables to allow them to be normalized in distribution. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; FIL, fasting insulin level; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell dysfunction; FIRI, fasting insulin resistance index; QUICKI, quantitative insulin sensitivity check index.

the result revealed no difference in prevalence statistically between benign and malignant ovarian neoplasms. This was in agreement with Serin *et al* (24), who reported that the IR index by HOMA is not a valid indicator for ovarian malignancy. A study by Lukanova *et al* (26) also reported no significant association of IR-related circulating blood marker [i.e., insulin growth factors binding proteins-3 (IGFBP-3)] with ovarian cancer risk. Hernandez *et al* (81) also reported no differences in IR markers, including FIL, in women with breast cancer (BC), while Kundaktepe *et al* (82) showed no differences in FPG and HOMA-IR between BC cases and healthy controls.

In contrast with the findings of the present study, Sun *et al* (16) found that the prevalence of post-menopausal malignant neoplasm of the ovary was higher in patients with IR (0.17 vs. 0.09%; P<0.05) with OR of 2.17 (95% CI: 1.22-3.89; P<0.05) than those who were insulin sensitive (16). Research in India discovered that a high level of FIL in ovarian neoplasm is associated with a greater risk for cancer development with an OR of 2.7 (95% CI: 1.00-6.67; P<0.05) (49). Otokozawa *et al* (25) also documented an increased risk of malignant ovarian neoplasm in the high tertile of FIL compared with the low tertile (P trend <0.001).

The lack of significance between the benign and malignant groups in the present study's findings may be due to the different proportions of subject BMIs, with higher rates of obese and overweight patients in the benign group. Meanwhile, the malignant group's BMI was more typically normal or underweight. Variations in study characteristics might be another cause for these discrepancies. Several factors influence serum IGF-I concentrations in individuals with IR, including age, nutritional intake, and underlying disease severity (83). A study discovered a tangible link between circulating IGF-I levels and the risk of getting ovarian cancer before age 55 (26); meanwhile, most of our patients had a younger age with a mean age of 42.9 years. The most recent studies studied IR and ovarian neoplasm in individuals who were primarily menopausal (16,24,49), which was not the case in the present study.

Table V. Differences in mean or median values of clinical characteristics of patients and metabolic parameters between non-insulin-resistant and insulin-resistant groups among benign and malignant ovarian neoplasms.

	Mean ± SD or median (IQR)					
	Benign neoplasms			Malignant neoplasms		
Variables	Non-IR (HOMA-IR <1.208)	IR (HOMA-IR ≥1.208)	P-value	Non-IR (HOMA-IR <1.208)	IR (HOMA-IR ≥1.208)	P-value
Age (years)	39.18±10.64	37.70±13.22	0.753[a]	46.11±7.88	50.71±10.19	0.239[a]
Menopausal age (years)	46.50 (43.00-50.75)	52.00 (50.00-52.00)	0.165[b]	48.00±1.85	48.20±7.15	0.940[a]
SBP (mmHg)	121.18±12.32	122.60±15.07	0.792[a]	130.50±16.96	126.57±21.23	0.632[a]
DBP (mmHg)	81.06±5.85	80.50±6.75	0.227[a]	83.83±6.51	86.14±7.99	0.462[a]
BMI (kg/m^2)	23.13±3.11	21.14±3.61	0.145[a]	18.66 (17.89-20.88)	18.61 (18.36-24.97)	0.671[b]
FPG (mg/dl)	82.06±6.05	92.00±10.59	0.004[a]	85.50±15.55	109.71±15.77	0.002[a]
FIL (μIU/ml)	3.60 (2.80-4.10)	7.95 (6.87-13.30)	<0.001[b]	3.15 (2.45-3.87)	5.60 (4.90-7.90)	0.001[b]
HOMA-β (%)	65.25 (49.20-101.83)	86.72 (64.84-249.04)	0.031[b]	47.53 (28.02-81.48)	65.03 (28.00-91.74)	0.672[b]
FIRI	0.66±0.19	1.91±0.57	<0.001[a]	0.62 (0.43-0.82)	1.37 (1.17-1.65)	<0.001[b]
QUICKI	0.41±0.20	0.34±0.14	<0.001[a]	0.41 (0.39-0.44)	0.36 (0.35-0.37)	<0.001[b]

[a]Student's t-test, equal variances assumed; [b]Mann-Whitney U test. SD, standard deviation; IQR, interquartile range; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; FIL, fasting insulin level; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell dysfunction; FIRI, fasting insulin resistance index; QUICKI, quantitative insulin sensitivity check index.

Table VI. Differences in mean or median values of patient's clinical characteristics and metabolic parameters between the two classes of body mass index among benign and malignant ovarian neoplasms.

	Mean ± SD or median (IQR)					
	Benign ovarian neoplasms			Malignant ovarian neoplasms		
Variables	Normal + underweight	Obese + overweight	P-value	Normal + underweight	Obese + overweight	P-value
Age (years)	39.29±12.60	37.92±10.50	0.764[a]	47.25±8.58	48.00±9.82	0.866[a]
Menopausal age (years)	49.00 (43.00-53.50)	48.50 (47.00-48.50)	>0.999[b]	49.00 (46.00-50.00)	49.50 (49.00-49.50)	0.611[b]
SBP (mmHg)	123.00±14.02	120.31±12.53	0.604[a]	126.45±16.52	141.20±20.12	0.100[a]
DBP (mmHg)	80.50±7.23	81.23±4.80	0.762[a]	83.30±6.97	89.20±4.15	0.085[a]
FPG (mg/dl)	86.50 (81.75-96.25)	80.00 (76.50-83.50)	0.017[b]	91.65±20.24	94.80±13.53	0.746[a]
FIL (μIU/ml)	4.80 (2.76-7.12)	4.00 (3.45-8.45)	0.560[b]	3.65±1.68	7.40±5.29	0.190[c]
HOMA-β (%)	62.23 (49.80-85.91)	102.86 (70.52-161.84)	0.023[b]	43.16 (27.77-73.44)	77.14 (57.40-110.45)	0.067[b]
FIRI	0.96 (0.51-1.58)	0.74 (0.61-1.77)	0.865[b]	0.69 (0.46-1.13)	0.98 (0.79-2.87)	0.089[b]
QUICKI	0.39±0.04	0.38±0.04	0.895[a]	0.40 (0.37-0.43)	0.38 (0.33-0.39)	0.097[b]

[a]Student's t-test, equal variances assumed; [b]Mann-Whitney U test; [c]Student's t-test, equal variances not assumed. SD, standard deviation; IQR, interquartile range; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; FIL, fasting insulin level; IR, insulin resistance; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell dysfunction; FIRI, fasting insulin resistance index; QUICKI, quantitative insulin sensitivity check index.

Menopause, which involves hormonal changes, might affect IR by contributing to increased visceral adiposity, which is linked to IR in post-menopausal women (17). This hypothesis might answer why the present study could not get significant differences between the benign and malignant case groups, mainly because of the generally younger age of patients involved in this study and fewer patients in our study group having menopausal status. Additionally, the prevalence of IR

Table VII. Differences in mean or median values of patient's clinical characteristics and metabolic parameters among the different histopathological types of malignant ovarian neoplasm.

Variables	Median (IQR)						
	Mucinous carcinoma	Clear cell carcinoma	Adenocarcinoma	Endometrioid carcinoma[b]	Serous carcinoma[b]	Mixed type[b]	P-value[c]
Age (years)	45.50 (40.00-53.25)	46.00 (40.25-50.50)	38.00 (31.50-52.00)	52.50	62.00	56.00	0.085
Menopausal age (years)	48.50 (45.75-49.75)	46.50[a]	43.00[a]	49.50	52.50	50.00	0.300
SBP (mmHg)	138.00 (116.75-152.75)	121.00 (106.00-140.25)	116.50 (115.00-130.75)	130.00	130.00	140.00	0.553
DBP (mmHg)	82.50 (77.25-90.75)	85.50 (80.00-90.50)	80.50 (77.00-87.00)	85.00	85.50	90.00	0.680
BMI (kg/m^2)	20.04 (17.89-24.84)	18.66 (17.98-25.44)	18.49 (17.24-18.93)	19.84	21.66	18.36	0.904
FPG (mg/dl)	87.50 (80.50-102.50)	87.50 (70.25-115.25)	83.50 (72.25-98.50)	92.50	96.00	126.00	0.651
FIL (μIU/ml)	3.50 (2.85-4.55)	3.00 (1.83-6.82)	5.30 (3.20-7.40)	3.10	6.55	4.90	0.245
HOMA-IR	0.73 (0.58-1.14)	0.73 (0.26-1.79)	0.82 (0.15-1.66)	0.70	1.56	1.52	0.433
HOMA-β (%)	49.30 (36.53-78.92)	26.13 (-20.15-87.48)	94.47 (57.23-201.30)	38.73	71.08	28.00	0.260
FIRI	0.66 (0.52-1.02)	0.66 (0.23-1.61)	0.99 (0.56-1.50)	0.63	1.40	1.37	0.293
QUICKI	0.40 (0.38-0.42)	0.40 (0.37-0.52)	0.37 (0.35-0.42)	0.41	0.36	0.36	0.308

[a]IQR could not be determined since few menopause patients with clear cell carcinoma (n=2) and adenocarcinoma (n=2); [b]IQR could not be determined since few cases of endometrioid carcinoma (n=2), serous carcinoma (n=2) and mixed type of malignant ovarian neoplasm (n=1); [c]P-value indicated the statistical differences between the six pathology types of malignant ovarian neoplasm using the Kruskal-Wallis test. IQR, interquartile range; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; FIL, fasting insulin level; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell dysfunction; FIRI, fasting insulin resistance index; QUICKI, quantitative insulin sensitivity check index.

is also closely related to obesity (84); by contrast, the present study had fewer obese and overweight participants, and in malignant cases, the subjects mainly had lower BMI; thus, the IR difference will also probably be statistically insignificant between the two groups.

Recent research into ovarian cancer has revealed that different histopathological types may have different risk factors, unique carcinogenesis, and distinct developmental pathways (85,86). Accordingly, the present study conducted a comparative histopathological analysis of malignant ovarian neoplasms related to clinical, metabolic, and IR indicators. The results, however, revealed no significant variation for these comparisons. Nonetheless, based on FIL, HOMA-IR, and FIRI markers, it was discovered that IR tended to be more prevalent in serous carcinoma groups. There has been a limited exploration into the various histopathological types of ovarian cancer and IR. The present study, however, corroborated previous findings in a case-control study, which reported that the proportion of MetS is more prominent in the serous

carcinoma group compared with the other histopathological groups (69.44% vs. 30.56%, P=0.411) (87). The highest median BMI score in the ovarian cancer patients in the present study was also found in the serous carcinoma group. This result supported evidence from a previous Mendelian randomization study, which indicated that genetically predicted increasing BMI (per 5 kg/m^2) was linked with an increased risk of low-grade serous ovarian cancers (87). Notably, a higher triacylglycerol level is associated with a greater risk of serous ovarian cancers (88). However, the sample size of each histopathological type of ovarian cancer in this provided data was small, making it challenging to draw convincing conclusions concerning these qualities. More research, therefore, is demanded to validate these findings.

Study on surrogate markers of IR between benign and malignant ovarian neoplasms. The measurement of IR should be seen as heralding the possibility of future changes in the understanding of ovarian neoplasm development. The HEC

is a standard and direct approach for estimating IR currently. However, because of the time and cost needed (89), its application in clinical practice is restricted. As a result, there is a need for accessible and approachable tests to evaluate insulin sensitivity/resistance (56). Several studies have focused on more practical ways of assessing IR using calculated markers (52,61,90).

As the main component of IR markers, FPG is crucial in determining the probability of reactive glucose and type 2 diabetes mellitus (T2DM) development. In the current investigation, the variations in IR markers and FPG parameters between the benign and malignant case groups were not statistically significant. However, there was a tendency for a slightly greater proportion of women with *de novo* high FPG in malignant cases rather than in benign cases. This insignificant difference might be related to the lower BMI status and metabolic parameters of the patients in the present study compared with those in other studies. Chronic hyperglycemia in patients with cancer may develop due to IR, which reduces glucose uptake in the muscle tissue and glucose storage in the liver, leading to elevated blood glucose levels (15).

Measuring the FIL and FPG is the most convenient and accurate method for determining IR in the normoglycemic population (91,92). The concentration of FIL was strongly correlated with the estimated insulin action (r=0.61; P<0.001) (93). However, it did not address the inappropriately low insulin secretion in the face of hyperglycemia, as found in diabetic or glucose-intolerant patients (56). Although a study with a cut-off of ≥7 μIU/ml indicated that the sensitivity of FIL was reasonably high (92.19%) with poor specificity (59.04%) for excluding IR (51), the present study discovered that FIL with the same cut-off could not distinguish the IR status difference in our case groups.

The HOMA model has proved to be a robust clinical and epidemiological tool for assessing IR (HOMA-IR) and β-cell function (HOMA-β). HOMA-IR correlates well with the HEC tests (94), with a sensitivity of 86%, specificity of 100%, and accuracy of 88% (66). No difference was found between benign and malignant cases using the Indonesian cut-off (63). HOMA-β is another computed variable demonstrating basal insulin secretion of pancreatic β-cells (95), indicating either normal, reduced, or excessive function. Insulin levels depend on the pancreatic β-cell effect on glucose concentrations. Thus, the diminished response of β-cell to secrete insulin with glucose stimulation will echo the impaired function of the β-cells of the subjects (62,96,97).

Similarly, IR is reflected in the diminished suppressive effect of insulin on hepatic glucose production (56). The present study found a statistically significant lower median score of HOMA-β in the malignant neoplasm group compared with the benign neoplasm group (49.33 vs. 75.79; P=0.011), and both of their median scores were classified as β-cell dysfunction (Table II). In the early phases of IR development, pancreatic β-cells release excessive insulin, resulting in hyperinsulinemia. Blood glucose levels will rise as β-cells become exhausted, depleted, and dysfunctional, eventually developing T2DM (98). This research has therapeutic implications, indicating that combining anti-tumor and anti-hyperglycemic medications may result in better tumor reduction outcomes (99). The present study observed the different mean scores of HOMA-β

between the IR and non-IR groups and between two classes of BMI classes among benign neoplasm cases; meanwhile, there was no statistical difference among malignant cases. It was probably due to the lower prevalence of obese and overweight participants in the malignant group, thus making the marker measurement results less reliable (64).

Another derived IR marker is FIRI, with a sensitivity of 86%, specificity of 100%, and accuracy of 88% (66). Among all patients with ovarian neoplasms, the present study revealed that the median score of FIRI was 0.76 (IQR: 0.54-1.35) and was not significantly different between the benign and malignant groups. FIRI is the most robust positively correlated parameter with FIL in the overall subjects, benign, and malignant case groups. It can indicate a cluster of pathologies, including hypercholesterolemia, T2DM, hypertension, and cardiovascular disease, indicating that they share a common etiology in IR (100). FIRI and HOMA reflect hepatic insulin sensitivity (90).

The last marker, QUICKI, has been found to have greater accuracy, stronger correlation (r=0.78), and improved positive predictive power to HEC compared with HOMA-IR (r=0.6) (56,61,101) in estimating insulin sensitivity (61,102). This marker has a sensitivity of 84%, specificity of 100%, and accuracy of 86% (66). The present study identified 86.5% of IR cases using this marker, similar to a prior study with a percentage of 84.4% (66). The median score of QUICKI in the present study was 0.39 (IQR: 0.36-0.42), with no significant difference between the two case groups, presumably because this index is lower in non-diabetic subjects than in patients with MetS, T2DM, and obesity (56). QUICKI is simply the logarithm of HOMA-IR, which explains the near-perfect correlation with HOMA, as seen in Fig. 2. Given the similarities between QUICKI and HOMA, these two approaches compare well (56) and have a strong correlation with FIL (P<0.01) (103). Nevertheless, according to the literature, HOMA-IR and QUICKI are limited due to their inability to provide information on the activity of insulin receptors in assessing IR (104).

Correlation between clinical features and surrogate markers. The correlation between markers and between markers and clinical variables related to insulin sensitivity (i.e., QUICKI) and IR (FIL, HOMA-IR, HOMA-β, FIRI) as reported by prior studies (66,104) are presented in Fig. 2. The strongest positive correlations were observed between FIL and FIRI among all neoplasm cases (r=0.974), benign (r=0.985) and malignant cases (ρ=0.933). FIL was correlated with HOMA-IR and HOMA-β in all three groups at decreasing strengths, respectively. Another study also found a positive correlation between FIL and HOMA-IR (r=0.93) and between FIL and FIRI (r=0.93) (66). Rutter *et al* (105) also report a correlation between FIL and HOMA-IR. Focusing on their link with clinical data, the present study found that HOMA-β was moderately correlated with BMI in the overall case group (ρ=0.417).

Similarly, the strongest significant inversely correlations were found between QUICKI and FIRI among the overall (r=-0.996), benign (r=-0.993), and malignant (ρ=-0.996) case groups. At a lesser strength, QUICKI was inversely correlated with FIL, HOMA-IR, FPG, and HOMA-β among the overall

case group, with FIL, HOMA-IR, HOMA-β, and FPG among the benign group and with FIL, HOMA-IR, and FPG among the malignant group. A similar result between QUICKI and FIL (r=-0.92) was also found in a previous study (66). Evaluating their correlation with clinical data, the current investigation discovered an inverse correlation between HOMA-β and FPG among overall cases and the benign case group, as well as between QUICKI and FPG in all three groups. These results were not entirely different from findings in a study on melanoma, which highlights the importance of HOMA-IR and QUICKI, which correlate between each marker and clinical data (104). Similarly, Conwell *et al* (106) reported that HOMA-IR, QUICKI, and FIL strongly correlate with IR. Overall, these findings confirm the reliability of the surrogate marker tests to determine IR status and their correlation with essential clinical data, as well as their interchangeability in assessing IR.

Compared to QUICKI and HOMA measurements, the FIL test exhibited excellent levels of sensitivity and specificity (107). In a previous study, Gates *et al* (100) discovered that FIRI substantially correlated with MetS-related characteristics. Meanwhile, Rudvik and Månsson (108) propose HOMA-IR, QUICKI, and FIRI as the best approach for estimating IR in clinical practice, attributed to their high correlation with HEC.

The mechanism between IR and malignant ovarian neoplasm is explained by the stimulation of IGF-1, a peptide hormone generated by excessive insulin. Anti-apoptotic and mitogenic properties of IGF-1 will promote tumor formation in ovarian epithelial cells (26,77,109). Karasik *et al* (110) confirm that IGF-1 concentrations are higher in cystic fluid from malignant ovarian neoplasms than in cystic fluid from benign ovarian neoplasms. IGF-1 is also released by hepatocytes and adipocytes, which explains why this peptide is linked to obesity (111,112). High insulin levels can promote peripheral estrogen transformation by affecting the expression of adipose tissue aromatase P450c17 in the ovarian glands (22,113). Together with insulin, estrogen will trigger the proliferation of the stroma, granulose cells, and theca cells (114,115).

Ovarian cancer is metabolically active and boosts its capacity to uptake larger volumes of glucose by upregulating the expression of glucose transporters (116-118). Chronic hyperglycemia creates DNA damage, cellular dysfunction, and damage to the ovarian epithelium by exposure to produced oxidative stress (i.e., reactive oxygen species) and the effects of glycation (119,120). In hyperglycemic environments, the interaction of advanced glycation end products and their receptors has been demonstrated to enhance tumor cell proliferation or invasiveness (121) by promoting systemic inflammation. High concentrations of cytokines (IL-1, TNF-α, IL-6, IL-8, and TGF-β) and prostaglandin, which promote mutagenesis and impede cellular recognition and destruction of tumors, are hypothesized to be connected with cancer development mechanistically (8,122). Higher glucose levels also contribute to increased angiogenesis in tumors by upregulating the expression of pro-angiogenic factors (e.g., VEGF) (123).

The critical finding of this study was that by applying multiple simple and specific cut-off surrogate markers, we could identify IR in more than two-thirds of this Indonesian case group with ovarian neoplasms. Considering the role of insulin in ovarian carcinogenesis, the results suggested that individuals with benign ovarian neoplasms and a higher BMI

status, particularly those with metabolic comorbidities, should be cautiously investigated for IR. A greater BMI should be a concern since it may alter circulating hormone levels and growth factors, leading to enhanced carcinogenesis and the possibility of malignant transformation (124).

Strengths and limitations. The present study was the first in Indonesia, to the best of the authors' knowledge, to report clinicopathological factors associated with IR in newly diagnosed Asian patients with ovarian neoplasm. It will be helpful for further scientific development and policy-makers due to a paucity of evidence in this area. Patients with T2DM and chronic inflammatory illnesses were also excluded from the study to avoid bias and false-positive high insulin levels.

However, although the outcomes of the present study are clinically worthwhile, several drawbacks might arise. First, this research was performed in a single center. Second, this cross-sectional study also does not prove causality; thus, it is challenging from a healthy population standpoint to infer if the diseases begin from IR to ovarian neoplasm or vice versa (8). The third limitation is that the sample size was relatively small; thus, type II errors may have occurred in the study. Nevertheless, earlier research on this issue also used a small sample size with similar settings (24,25,49,59) and the sample size of the present study was more extensive than those. Fourth, the present study did not recruit a healthy control group, making it impossible to assess and compare the development of the neoplasm case group to a normal state. The present study also did not use the standard technique to confirm IR (i.e., HEC) for this study (125); however, WHO has suggested surrogate markers to be diagnostic tools for IR in epidemiological research (126). Sixth, the cut-offs adopted in this study were not entirely based on the Indonesian women population with ovarian neoplasm because no initial investigation had established those cut-offs for Indonesians. Finally, the pre-menopausal and post-menopausal groups for each case group (benign and malignant) were not studied because their proportions were unequal.

In conclusion, there was no significant difference in IR between benign and malignant ovarian neoplasms among Indonesian non-diabetic women, as measured by numerous surrogate markers of IR. However, benign ovarian neoplasms tended to have a slightly higher proportion of IR. A tendency for a slightly higher proportion of IR was also found in advanced-stage cancer and serous carcinoma. QUICKI is likely superior in showing the highest prevalence of IR among the three groups. The present study also discovered considerable β-cell dysfunction in both case groups, with a more severe occurrence in malignant neoplasms, indicating early MetS and possible correlations to IR. Since insulin affects multiple pathways signaling cancer development, monitoring FIL, FPG, and other IR surrogates might be practical and integrative approaches to therapeutic cancer targets. To better understand the effect of IR on ovarian carcinogenesis and progression, a multicenter and population-based study with long-term follow-up on women with ovarian neoplasms should be conducted. It is also necessary to adjust BMI, age, menopausal status, comorbidities, and histopathological diagnosis to precisely stratify susceptibility to IR. Future research should measure other IR surrogate markers, including the glucose/insulin ratio, insulinogenic

index, Matsuda index, Gutt index, Stumvoll index, Avignon index, oral glucose insulin sensitivity index, sex hormones, leptin and other inflammatory markers (56). Investigations should also focus on more specific markers like IGF-I and IGFBP-3, which might be more accurate in distinguishing between benign and malignant ovarian neoplasms.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

HW was the principal investigator of this study, acquired funding, and controlled the decision to publish. HW, MH and ISF confirm the authenticity of all the raw data and accepted full responsibility for the overall content of the work. HW, MH, and ISF conceptualized the study, performed the investigation, designed the methodology, and provided the resources. HW and MH contributed to the analysis and drafted the manuscript. MH and ISF collected the data and performed the project administration. MH was entirely responsible for software utilization, data cleaning, and visualization of research findings. HW, FK, KHN, TDA, TWU and ADP performed the cancer staging, supervised the study and validated all data analyses. All authors critically revised the manuscript for important intellectual content. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Faculty of Medicine, Universitas Indonesia, with the ethical clearance number KET-1091/UN2. F1/ETIK/PPM.00.02/2019 and protocol number 19-07-0831. Written informed consent has been obtained from all patients involved in the study.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71: 209-249, 2021.

2. Teng Z, Han R, Huang X, Zhou J, Yang J, Luo P and Wu M: Increase of incidence and mortality of ovarian cancer during 2003-2012 in Jiangsu Province, China. Front Public Health 4: 146, 2016.

3. Winarto H, Welladatika A, Habiburrahman M, Purwoto G, Kusuma F, Utami TW, Putra AD, Anggraeni T and Nuryanto KH: Overall survival and related factors of advanced-stage epithelial ovarian cancer patients underwent debulking surgery in Jakarta, Indonesia: A single-center experience. Open Access Maced J Med Sci 10: 265-280, 2022.

4. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL: Ovarian cancer statistics, 2018. CA Cancer J Clin 68: 284-296, 2018.

5. Aziz MF: Gynecological cancer in Indonesia. J Gynecol Oncol 20: 8-10, 2009.

6. Devouassoux-Shisheboran M and Genestie C: Pathobiology of ovarian carcinomas. Chin J Cancer 34: 50-55, 2015.

7. Beauchamp MC, Yasmeen A, Knafo A and Gotlieb WH: Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol 2010: 257058, 2010.

8. Kellenberger LD, Bruin JE, Greenaway J, Campbell NE, Moorehead RA, Holloway AC and Petrik J: The role of dysregulated glucose metabolism in epithelial ovarian cancer. J Oncol 2010: 514310, 2010.

9. Uzunlulu M, Telci Caklili O and Oguz A: Association between metabolic syndrome and cancer. Ann Nutr Metab 68: 173-179, 2016.

10. Tseng YH, Ueki K, Kriauciunas KM and Kahn CR: Differential roles of insulin receptor substrates in the anti-apoptotic function of insulin-like growth factor-1 and insulin. J Biol Chem 277: 31601-31611, 2002.

11. Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y and Seke Etet PF: Insulin resistance and cancer: The role of insulin and IGFs. Endocr Relat Cancer 20: R1-R17, 2013.

12. Atsumi T: Diabetes and risk of cancer. Diabetol Int 6: 190-192, 2015.

13. Joung KH, Jeong JW and Ku BJ: The association between type 2 diabetes mellitus and women cancer: The epidemiological evidences and putative mechanisms. Biomed Res Int 2015: 920618, 2015.

14. Igwe EO, Azman A, Nordin A and Mohtarrudin N: Association between HOMA-IR and Cancer in a Medical Centre in Selangor, Malaysia. IJPHCS 2: 21-34, 2015.

15. Ekinci O, Eren T, Kurtoglu Yakici M, Gapbarov A, Aydemir MA, Saglam ZA and Alimoglu O: Relationship Between Metabolic Syndrome and Postmenopausal Breast Cancer. Cir Esp (Engl Ed) 98: 540-546, 2020 (In English, Spanish).

16. Sun W, Lu J, Wu S, Bi Y, Mu Y, Zhao J, Liu C, Chen L, Shi L, Li Q, et al: Association of insulin resistance with breast, ovarian, endometrial and cervical cancers in non-diabetic women. Am J Cancer Res 6: 2334-2344, 2016.

17. Nam S, Park S, Park HS, Kim S, Kim JY and Kim SI: Association between insulin resistance and luminal B subtype breast cancer in postmenopausal women. Medicine (Baltimore) 95: e2825, 2016.

18. Gennari A, Puntoni M, Nanni O, De Censi A, Bruzzi P, Paleari L Freschi A, Amaducci L, Bologna A, Gianni L and Amadori D: Impact of insulin resistance (IR) on the prognosis of metastatic breast cancer (MBC) patients treated with first-line chemotherapy (CT). J Clin Oncol 32 (Suppl 15): S514, 2014.

19. Doğan İ, Ürün Y and Onur H: Effects of Adjuvant Chemotherapy on Insulin Resistance in Patients with Early Breast Cancer. Cam and Sakura Med J 2: 8-13, 2022.

20. Alan O, Akin Telli T, Aktas B, Koca S, Ökten IN, Hasanov R, Basoglu T, Arikan R, Demircan NC, Ercelep O, et al: Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment? World J Surg Oncol 18: 242, 2020.

21. Martín-Manzo MV, Lara C, Vargas-de-Leon C, Carrero J, Queipo G, Fonseca-Sanchez M, Mejia-Dominguez NR, Kershenobich D, Mummidi S, Zentella-Dehesa A and Hernandez J: Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells. Pathol Oncol Res 25: 1233-1243, 2019.

22. Lai Y and Sun C: Association of abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer. Oncol Lett 15: 2173-2178, 2018.

23. Momenimovahed Z, Tiznobaik A, Taheri S and Salehiniya H: Ovarian cancer in the world: Epidemiology and risk factors. Int J Womens Health 11: 287-299, 2019.

24. Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B and Unluhizarci K: Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecol Endocrinol 24: 117-121, 2008.

25. Otokozawa S, Tanaka R, Akasaka H, Ito E, Asakura S, Ohnishi H, Saito S, Miura T, Saito T and Mori M: Associations of serum isoflavone, adiponectin and insulin levels with risk for epithelial ovarian cancer: Results of a case-control study. Asian Pac J Cancer Prev 16: 4987-4991, 2015.

26. Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, *et al*: Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 101: 549-554, 2002.

27. Dahlan MS: Sample Size in Medical and Health Research. 5th edition. Epidemiologi Indonesia, Jakarta, 2019 (In Indonesian).

28. Sharma SK, Mudgal SK, Thakur K and Gaur R: How to calculate sample size for observational and experiential nursing research studies? Natl J Physiol Pharm Pharmacol 10: 1-8, 2020.

29. Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S, Van Holsbeke C, Savelli L, Fruscio R, Lissoni AA, *et al*: Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: Prospective validation by IOTA group. BMJ 341: c6839, 2010.

30. Abramowicz JS and Timmerman D: Ovarian mass-differentiating benign from malignant: The value of the International Ovarian Tumor Analysis ultrasound rules. Am J Obstet Gynecol 217: 652-660, 2017.

31. Badan Pusat Statistik/BPS-Statistics Indonesia: Concept of Population, Age, Marital Status, Children Ever Born, Children Still Alive, and Place of Birth in Indonesia. Concept, 2021. https://www.bps.go.id/subject/12/kependudukan.html. Accessed December 10, 2021.

32. Mulyana W: Rural-urban linkages: Indonesia case study. Working Group: Development with Territorial Cohesion. Territorial Cohesion for Development Program Rimisp, pp1-36, 2014.

33. Badan Pusat Statistik/BPS-Statistics Indonesia: Regulation of the Head of the Central Statistics Agency Number 120 of 2020: Classification of Urban and Rural Areas in Java, Indonesia [In Indonesian]. In: Book Chapter Java, 2nd ed. BPS, Jakarta, pp1-692, 2010.

34. Badan Pusat Statistik/BPS-Statistics Indonesia: Regulation of the Head of the Central Statistics Agency Number 120 of 2020: Classification of Urban and Rural Areas in Sumatra, Indonesia [In Indonesian]. In: Book Chapter Sumatera, 2nd ed. BPS, Jakarta, pp1-681, 2010.

35. Klar M, Hasenburg A, Hasanov M, Hilpert F, Meier W, Pfisterer J, Pujade-Lauraine E, Herrstedt J, Reuss A and du Bois A: Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. Eur J Cancer 66: 114-124, 2016.

36. Lalrinpuii E, Bhageerathy PS, Sebastian A, Jeyaseelan L, VinothaThomas, Thomas A, Chandy R and Peedicayil A: Ovarian Cancer in Young Women. Indian J Surg Oncol 8: 540-547, 2017.

37. Encinas G, Maistro S, Pasini FS, Katayama ML, Brentani MM, Bock GH and Folgueira MA: Somatic mutations in breast and serous ovarian cancer young patients: A systematic review and meta-analysis. Rev Assoc Med Bras (1992) 61: 474-483, 2015.

38. Bozas G, Dimopoulos MA, Kastritis E, Efstathiou E, Koutsoukou V, Rodolakis A, Vlahos G, Voulgaris Z, Papageorgiou T, Gika D, *et al*: Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: A single institution experience. Oncology 70: 265-272, 2006.

39. Winarto H, Habiburrahman M, Dorothea M, Wijaya A, Nuryanto KH, Kusuma F, Utami TW and Anggraeni TD: Knowledge, attitudes, and practices among Indonesian urban communities regarding HPV infection, cervical cancer, and HPV vaccination. PLoS One 17: e0266139, 2022.

40. 4Berek JS, Renz M, Kehoe S, Kumar L and Friedlander M: FIGO Cancer Report 2021: Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet 155: 61-85, 2021.

41. World Health Organization and International Agency for Research on Cancer. World Health Organization: WHO Classification of Tumours: Female Genital Tumours. 5th edition. WHO, Geneva, Switzerland, pp31-163, 2021.

42. Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M and Allemani C; & the CONCORD Working Group: The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol 144: 405-413, 2017.

43. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, *et al*: 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 75: 1334-1357, 2020.

44. National Health and Nutrition Examination Survey and Center of Disease Control and Prevention: Anthropometry Procedures Manual. CDC2: 1-65, 2007.

45. Lim JU, Lee JH, Kim JS, Hwang YI, Kim TH, Lim SY, Yoo KH, Jung KS, Kim YK and Rhee CK: Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. Int J Chron Obstruct Pulmon Dis 12: 2465-2475, 2017.

46. Cleveland Clinic: Fasting Blood Sugar Test. Diagnostics & Testing, 2021. https://my.clevelandclinic.org/health/diagnostics/21952-fasting-blood-sugar. Accessed December 10, 2021.

47. Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, Gude F, García F, De Francisco A and Quintela AG: Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: Effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord 13: 47, 2013.

48. Farahani H, Mahmoudi T, Asadi A, Nobakht H, Dabiri R and Hamta A: Insulin Resistance and Colorectal Cancer Risk: The Role of Elevated Plasma Resistin Levels. J Gastrointest Cancer 51: 478–483, 2020.

49. Gupta RK, Dholariya SJ, Kaushik S, Gupta SK, Tripathi R and Jain SL: Hyperinsulinemia and Hypoadiponectinemia are Associated with increased risk for occurrence of ovarian cancer in non-diabetic women of North Indian Population. Indian J Clin Biochem 36: 221-227, 2021.

50. American Diabetes Association (ADA): Diagnosis of Diabetes Mellitus. ADA, Arlington, VA, 2022.

51. Lunger F, Wildt L and Seeber B: Accurate screening for insulin resistance in PCOS women using fasting insulin concentrations. Gynecol Endocrinol 29: 541-544, 2013.

52. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.

53. Onishi Y, Hayashi T, Sato KK, Ogihara T, Kuzuya N, Anai M, Tsukuda K, Boyko EJ, Fujimoto WY and Kikuchi M: Fasting tests of insulin secretion and sensitivity predict future prediabetes in Japanese with normal glucose tolerance. J Diabetes Investig 1: 191-195, 2010.

54. Yamauchi K, Sato Y, Nakasone Y and Aizawa T: Comparison of HOMA-IR, HOMA-β% and disposition index between US white men and Japanese men in Japan in the ERA JUMP study: Was the calculation of disposition index legitimate? Diabetologia 58: 1679-1680, 2015.

55. Imano H, Kitamura A, Yamagishi K, Kiyama M, Ohira T, Cui R, Umesawa M, Okada T and Iso H; CIRCS Investigators: Abstract P455: Insulin Resistance, Secretion and Risk of Incident Coronary Heart Disease in Non-diabetic Japanese Population: The Circulatory Risk in Communities Study. Circulation 129: AP455, 2014.

56. Singh B and Saxena A: Surrogate markers of insulin resistance: A review. World J Diabetes 1: 36-47, 2010.

57. Duncan MH, Singh BM, Wise PH, Carter G and Alaghband-Zadeh J: A simple measure of insulin resistance. Lancet 346: 120-121, 1995.

58. Tsarouhas K, Tsitsimpikou C, Haliassos A, Georgoulias P, Koutsioras I, Kouretas D, Kogias J, Liosis I, Rentoukas E and Kyriakides Z: Study of insulin resistance, TNF-α, total antioxidant capacity and lipid profile in patients with chronic heart failure under exercise. In Vivo 25: 1031-1037, 2011.

59. Farkas GJ, Gordon PS, Trewick N, Gorgey AS, Dolbow DR, Tiozzo E, Berg AS and Gater DR Jr: Comparison of various indices in identifying insulin resistance and diabetes in chronic spinal cord injury. J Clin Med 10: 5591, 2021.

60. Gordon PS, Farkas GJ and Gater DR Jr: Neurogenic Obesity-Induced Insulin Resistance and Type 2 Diabetes Mellitus in Chronic Spinal Cord Injury. Top Spinal Cord Inj Rehabil 27: 36-56, 2021.

61. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G and Quon MJ: Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2402-2410, 2000.

62. Matsuda M and DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.
63. Livy B Pratisthita, Purnamasari D, Rizka A, Soewondo P, Yunir E and Tahapary DL: The Cut-off Values of Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) in Indonesian Rural Population. Lancet Preprint 6: 7-20, 2020.
64. Rahman MN, Sukmawati IR, Puspitasari IM and Fattah M: Serum free zinc as a predictor for excessive function of pancreatic beta-cells in central-obese men. Indones Biomed J 11: 262-266, 2019.
65. AlZadjali MA, Godfrey V, Khan F, Choy A, Doney AS, Wong AK, Petrie JR, Struthers AD and Lang CC: Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol 53: 747-753, 2009.
66. Kaur N, Gitanjali, Garg R, Tapasvi C, Chawla S and Kaur N: Correlation of Surrogate Markers of Insulin Resistance with Fasting Insulin in Type 2 Diabetes Mellitus Patients: A Study of Malwa Population in Punjab, India. J Lab Physicians 13: 238-244, 2021.
67. Diebetes.co.uk: Blood Sugar Converter. Calculators and Tools, 2022. https://www.diabetes.co.uk/blood-sugar-converter.html. Accessed April 12, 2022.
68. Katalin C: Surrogate Measures of Insulin Resistance in Middle-aged Non-diabetic Subjects. Acta Med Marisiensis 59: 279–284, 2014.
69. Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, Anderson ML, Ramondetta LM, Tortolero-Luna G, Urbauer DL, et al: Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol 204: 355.e1-7, 2011.
70. Elm E von, Altman DG, Egger M, Pocock SJ, Gøtzsche PC and Vandenbroucke JP: Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335: 806 LP-808, 2007.
71. Statistic Tutor: Spearman's correlation, 2021. http://www.statstutor.ac.uk/resources/uploaded/spearmans.pdf. Accessed December 10, 2021.
72. Beavis AL, Smith AJ and Fader AN: Lifestyle changes and the risk of developing endometrial and ovarian cancers: Opportunities for prevention and management. Int J Womens Health 8: 151-167, 2016.
73. Szpurek D, Moszynski R, Szubert S and Sajdak S: Urban and rural differences in characteristics of ovarian cancer patients. Ann Agric Environ Med 20: 390-394, 2013.
74. Saccò M, Meschi M, Regolisti G, Detrenis S, Bianchi L, Bertorelli M, Pioli S, Magnano A, Spagnoli F, Giuri PG, et al: The relationship between blood pressure and pain. J Clin Hypertens (Greenwich) 15: 600-605, 2013.
75. El-Atat FA, Stas SN, McFarlane SI and Sowers JR: The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 15: 2816-2827, 2004.
76. Pérez-Pérez A, Sánchez-Jiménez F, Vilariño-García T and Sánchez-Margalet V: Role of Leptin in Inflammation and Vice Versa. Int J Mol Sci 21, 2020.
77. Orgel E and Mittelman SD: The links between insulin resistance, diabetes, and cancer. Curr Diab Rep 13: 213–222, 2013.
78. Kim SI, Kim HS, Kim TH, Suh DH, Kin K, No JH, Chung HH, Kim YB and Song YS: Impact of underweight after treatment on prognosis of advanced-stage ovarian cancer. J Immunol Res 2014: 1–8, 2014.
79. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Gao F and Herzog TJ: Relationship of ovarian neoplasms and body mass index. J Reprod Med 50: 595–602, 2005.
80. Leitzmann MF, Koebnick C, Danforth KN, et al: Body mass index and risk of ovarian cancer. Cancer 115: 812–822, 2009.
81. Hernandez AV, Guarnizo M, Miranda Y, Pasupuleti V, Deshpande A, Paico S, Lenti H, Ganoza S, Montalvo L, Thota P and Lazaro H: Association between insulin resistance and breast carcinoma: A systematic review and meta-analysis. PLoS One 9: e99317, 2014.
82. Kundaktepe BP, Durmus S, Cengiz M, Kundaktepe FO, Sozer V, Papila C, Gelisgen R and Uzun H: The significance of insulin resistance in nondiabetic breast cancer patients. J Endocrinol Metab 11: 42-48, 2021.
83. Gómez JM, Maravall FJ, Gómez N, Navarro MA, Casamitjana R and Soler J: Interactions between serum leptin, the insulin-like growth factor-I system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected. Clin Endocrinol (Oxf) 58: 213-219, 2003.
84. Bjørge T, Lukanova A, Tretli S, Manjer J, Ulmer H, Stocks T, Selmer R, Nagel G, Almquist M, Concin H, et al: Metabolic risk factors and ovarian cancer in the Metabolic Syndrome and Cancer project. Int J Epidemiol 40: 1667-1677, 2011.
85. Craig ER, Londoño AI, Norian LA and Arend RC: Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review. Gynecol Oncol 143: 674-683, 2016.
86. Khanlarkhani N, Azizi E, Amidi F, Khodarahmian M, Salehi E, Pazhohan A, Farhood B, Mortezae K, Goradel NH and Nashtaei MS: Metabolic risk factors of ovarian cancer: A review. JBRA Assist Reprod 26: 335-347, 2022.
87. Dixon SC, Nagle CM, Thrift AP, Pharoah PD, Pearce CL, Zheng W, Painter JN; AOCS Group & Australian Cancer Study (Ovarian Cancer), Chenevix-Trench G, Fasching PA, et al: Adult body mass index and risk of ovarian cancer by subtype: A Mendelian randomization study. Int J Epidemiol 45: 884-895, 2016.
88. Zeleznik OA, Eliassen AH, Kraft P, Poole EM, Rosner BA, Jeanfavre S, Deik AA, Bullock K, Hitchcock DS, Avila-Pacheco J, et al: A prospective analysis of circulating plasma metabolites Associated with ovarian cancer risk. Cancer Res 80: 1357-1367, 2020.
89. Lee S, Choi S, Kim HJ, Chung YS, Lee KW, Lee HC, Huh KB and Kim DJ: Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non-diabetic adults. J Korean Med Sci 21: 695-700, 2006.
90. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T and Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23: 57-63, 2000.
91. Robbins DC, Andersen L, Bowsher R, Chance R, Dinesen B, Frank B, Gingerich R, Goldstein D, Widemeyer HM, Haffner S, et al: Report of the American Diabetes Association's Task Force on standardization of the insulin assay. Diabetes 45: 242-256, 1996.
92. Mack R, Skurnick B, Sterling-Jean Y, Pedra-Nobre M and Bigg D: Fasting insulin levels as a measure of insulin resistance in American blacks. J Med 34: 31-38, 2003.
93. Yeni-Komshian H, Carantoni M, Abbasi F and Reaven GM: Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 23: 171-175, 2000.
94. Buchanan TA, Watanabe RM and Xiang AH: Limitations in surrogate measures of insulin resistance. J Clin Endocrinol Metab 95: 4874-4876, 2010.
95. Haffner SM, Miettinen H and Stern MP: The homeostasis model in the San Antonio Heart Study. Diabetes Care 20: 1087-1092, 1997.
96. Legro RS, Finegood D and Dunaif A: A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 83: 2694-2698, 1998.
97. Jørgensen SW, Hjort L, Gillberg L, Justesen L, Madsbad S, Brøns C and Vaag AA: Impact of prolonged fasting on insulin secretion, insulin action, and hepatic versus whole body insulin secretion disposition indices in healthy young males. Am J Physiol Endocrinol Metab 320: E281-E290, 2021.
98. Habib SS, Eshki A, AlTassan B, Fatani D, Helmi H and AlSaif S: Relationship of serum novel adipokine chemerin levels with body composition, insulin resistance, dyslipidemia and diabesity in Saudi women. Eur Rev Med Pharmacol Sci 21: 1296-1302, 2017.
99. Pavelić K, Slijepcević M, Pavelić J, Ivić J, Audy-Jurković S, Pavelić ZP and Boranić M: Growth and treatment of Ehrlich tumor in mice with alloxan-induced diabetes. Cancer Res 39: 1807-1813, 1979.
100. Gates JR, Parpia B, Campbell TC and Chen J: Evaluation of the FIRI (Fasting Insulin Resistance Index) and selected plasma parameters associated with insulin resistance as predictors of cardiovascular mortality in rural Chinese women. Asia Pac J Clin Nutr 6: 200-202, 1997.
101. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, Quon MJ and Baron AD: Repeatability characteristics of simple indices of insulin resistance: Implications for research applications. J Clin Endocrinol Metab 86: 5457-5464, 2001.
102. Chen H, Sullivan G, Yue LQ, Katz A and Quon MJ: QUICKI is a useful index of insulin sensitivity in subjects with hypertension. Am J Physiol Endocrinol Metab 284: E804-E812, 2003.

103. Hettihewa LM, Palangasinghe S, Jayasinghe SS, Gunasekara SW and Weerarathna TP: Comparison of insulin resistance by indirect methods-HOMA, QUICKI and McAuley-With fasting insulin in patients with type 2 diabetes in Galle, Sri Lanka: A pilot study. Online J Health Allied Sci 5: 1-8, 2006.
104. Scoppola A, Strigari L, Barnabei A, Petasecca P, De Galitiis F, Fulgenzi CAM, Roselli M, De Lorenzo A, Di Renzo L, Marchetti P and Torino F: Insulin resistance as a risk factor for cutaneous melanoma. A case control study and risk-assessment nomograms. Front Endocrinol (Lausanne) 10: 757, 2019.
105. Rutter MK, Wilson PWF, Sullivan LM, Fox CS, D'Agostino RB Sr and Meigs JB: Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardio-vascular disease. Circulation 117: 1003-1009, 2008.
106. Conwell LS, Trost SG, Brown WJ and Batch JA: Indexes of insulin resistance and secretion in obese children and adolescents: A validation study. Diabetes Care 27: 314-319, 2004.
107. Garg MK, Tandon N, Marwaha RK and Singh Y: Evaluation of surrogate markers for insulin resistance for defining meta-bolic syndrome in urban Indian adolescents. Indian Pediatr 51: 279-284, 2014.
108. Rudvik A and Månsson M: Evaluation of surrogate measures of insulin sensitivity-correlation with gold standard is not enough. BMC Med Res Methodol 18: 64, 2018.
109. Coppola D, Saunders B, Fu L, Mao W and Nicosia SV: The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression. Cancer Res 59: 3264-3270, 1999.
110. Karasik A, Menczer J, Pariente C and Kanety H: Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 78: 271–276, 1994.
111. Holly J: Insulin-like growth factor-1 and risk of breast cancer. Lancet 352: 1388, 1998.
112. D'Esposito V, Passaretti F, Hammarstedt A, Liguoro D, Terracciano D, Molea G, Canta L, Miele C, Smith U, Beguinot F and Formisano P: Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia 55: 2811-2822, 2012.
113. Sanchez-Garrido MA and Tena-Sempere M: Metabolic dysfunc-tion in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab 35, 2020.
114. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, Kihara S and Walsh K: Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 117: 375-386, 2007.
115. Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC and Conover CA: Functional insulin receptors on human epithelial ovarian carcinoma cells: Implications for IGF-II mitogenic signaling. Endocrinology 143: 3259-3267, 2002.
116. Lutz AM, Ray P, Willmann JK, Drescher C and Gambhir SS: 2-Deoxy-2-[F-18]fluoro-D-glucose accumulation in ovarian carcinoma cell lines. Mol Imaging Biol 9: 260-266, 2007.
117. Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M and Kikkawa F: Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol 98: 11-18, 2005.
118. Tsukioka M, Matsumoto Y, Noriyuki M, Yoshida C, Nobeyama H, Yoshida H, Yasui T, Sumi T, Honda K and Ishiko O: Expression of glucose transporters in epithelial ovarian carcinoma: Correlation with clinical characteristics and tumor angiogenesis. Oncol Rep 18: 361-367, 2007.
119. Sheetz MJ and King GL: Molecular understanding of hypergly-cemia's adverse effects for diabetic complications. JAMA 288: 2579-2588, 2002.
120. Yamagishi S, Nakamura K, Inoue H, Kikuchi S and Takeuchi M: Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients. Med Hypotheses 64: 1208-1210, 2005.
121. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, *et al*: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360, 2000.
122. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M and Schlesselman JJ: Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11: 111-117, 2000.
123. Benjamin LE: Glucose, VEGF-A, and diabetic complications. Am J Pathol 158: 1181-1184, 2001.
124. Wang M, Cheng N, Zheng S, Wang D, Hu X, Ren X, Pei H, Ma H, Mu H and Bai Y: Metabolic syndrome and the risk of breast cancer among postmenopausal women in North-West China. Climacteric 18: 852-858, 2015.
125. DeFronzo RA, Tobin JD and Andres R: Glucose clamp tech-nique: A method for quantifying insulin secretion and resistance. Am J Physiol 237: E214-E223, 1979.
126. Alberti KG and Zimmet PZ: Definition, diagnosis and classifica-tion of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998.